Acquired BTK and PLCG2 Mutations May Not Drive Progression After Zanubrutinib/Ibrutinib Treatment in Relapsed CLL : vimarsana.com

The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.

Related Keywords

Jennifer Brown , Chronic Lymphocytic Leukemia At Dana Farber Cancer Institute , Chronic Lymphocytic Leukemia , Dana Farber Cancer Institute , Patients With Relapsed Cll Treated Zanubrutinib Or Ibrutinib In The Phase 3 Alpine Study , Btk Or Plcg2 Mutation , Disease Progression , Primary Drivers Of Resistance And Relapse , 2023 Ash Annual Meeting ,